Tag: Corporate

Beam Global is relocating manufacturing from San Diego to Yuma, Arizona, reducing costs, improving margins, and supporting future growth.

New headquarters strengthens CDS' US-based infrastructure and expands capacity for dealer support, training, engineering, fulfillment, and long-term innovationIRVINE, Calif., June 25, 2026 /PRNewswire/ --...

Herbalife–IIT Madras Centre of Excellence aims to position India as a global leader in sustainable biomanufacturing and next-generation plant-derived health and wellness productsCHENNAI, India,...

PERTH, Australia, June 25, 2026 /CNW/ - Westgold Resources Limited (ASX | TSX: WGX – Westgold or the Company) today announces the retirement of...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

TORONTO, June 25, 2026 /CNW/ - Power Metallic Mines Inc. (the "Company" or "Power Metallic") (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to announce...

DEMIRE is expanding its ESG database to cover almost its entire portfolio and is continuing to drive forward decarbonization

DEMIRE baut ESG-Datenbasis auf nahezu gesamtes Portfolio aus und treibt Dekarbonisierung weiter voran

TAIPEI, June 25, 2026 /PRNewswire/ -- Led by the Department of Economic Development, Taipei City Government, the StartUP@Taipei program brought 10 Taipei-based AI companies...

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

Global market projected to grow at a CAGR of 13.5% from 2026 to 2033 as pharmaceutical, food, and healthcare industries increasingly rely on advanced...